Thrasos secures funding for acute kidney injury treatment research Globe and Mail Montreal-based company Thrasos Therapeutics says it has completed a $35-million (U.S.) financing deal to develop THR-184, its lead product candidate for the treatment of acute kidney injury (AKI). The venture capital funding is part of a new approach ... Thrasos Secures $35 Million to Fund THR-184 Phase 2 Clinical Program for ... GlaxoSmithKline backs Canadian biotech in $35M deal for kidney drug |
